2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
10
Gastro-enteropancreatic neuroendocrine tumor
4
Pheochromocytoma
2
Paraganglioma
2
Vipoma
1
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Meningioma
1
Lymphoma
1
Insulinoma
1
Gastrinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoid Tumor
1
Interventions
pembrolizumab
3
Drug Therapy
3
Quality of Life
2
Proton Therapy
2
Immunotherapy
2
Blood Specimen Collection
2
ribociclib
1
palbociclib
1
napabucasin
1
fludarabine
1
epacadostat
1
bosutinib
1
amrubicin
1
alovudine
1
Tumor Burden
1
Sunitinib
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Plicamycin
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Histocompatibility Testing
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymus Neoplasms
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled